Docetaxel +Cisplatin

Phase 3Small molecule

Docetaxel +Cisplatin is one of 113 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Gastric CancerActive, not recruiting

Lung CarcinomaActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Lung CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Docetaxel +Cisplatin

HHenan Cancer Hospital

Phase 3

2 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Not yet recruiting

Breast Cancer

NCT07136974

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07136974·280 enrolled

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Withdrawn·HHenan Cancer Hospital·Phase 3·NCT05474690

Neoadjuvant Treatment1 trial

Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

Completed·HHenan Cancer Hospital·Phase 2·NCT04664972·212 enrolled

Nasopharyngeal Cancer1 trial

Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

Unknown status·SSamsung Medical Center·Phase 2·NCT01312311·51 enrolled

Non-Small Cell Lung Cancer1 trial

Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)

Completed·NNational Taiwan University Hospital·Phase 2·NCT00173888·15 enrolled

Gastric Cancer1 trial

Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT00980603·144 enrolled

1 more indication

Lung Carcinoma1 trial

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

Terminated·SSpanish Lung Cancer Group·Phase 3·NCT00617656·382 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Docetaxel +Cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel +Cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetaxel +Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHenan Cancer Hospital

Docetaxel +Cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Breast Cancer2 trials

Neoadjuvant Treatment1 trial

Nasopharyngeal Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Gastric Cancer1 trial

Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News